Matrix Capital Management Company, LP — Q4 2025 13F-HR

← Matrix Capital Management Company, LP

Q4 2025 · 13F-HR

Matrix Capital Management Company, LPholdings as filed

Filed 2026-02-13 · accession 0001172661-26-000728

$57.6M

Reported value

Positions

2025-12-31

Period end

View analyzed profile →PRO

The Brief · Matrix Capital Management Company, LP · Q4 2025

AI · grounded in 13F

Matrix Capital Management Company, LP closed its entire position in Zentalis Pharmaceuticals Inc ZNTL, reducing its holdings by $21.1M. The fund also trimmed its stake in Maze Therapeutics Inc MAZE by 70.97%. These moves reduced the fund's total position count to two.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
05153U107	AURA	AURA BIOSCIENCES INC	$37.7M	65.5%	6,922,870	Common	SOLE
578784100	MAZE	MAZE THERAPEUTICS INC	$19.9M	34.5%	480,000	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.